[The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
D000636:Aminosalicylic Acids / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008297:Male; D012293:Rifampin / Q000009:adverse effects; D013307:Streptomycin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Nebenwirkungen zweier Therapiekombinationen (SM, PAS, INH/RMP, INH, EMB) in der Intensivbehandlungsphase der Lungentuberkulose